146 related articles for article (PubMed ID: 10953136)
1. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer.
Chon JK; Jacobs SC; Naslund MJ
J Urol; 2000 Sep; 164(3 Pt 1):735-7. PubMed ID: 10953136
[TBL] [Abstract][Full Text] [Related]
2. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
[TBL] [Abstract][Full Text] [Related]
3. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
Mariani AJ; Glover M; Arita S
J Urol; 2001 Jan; 165(1):104-7. PubMed ID: 11125375
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
5. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer.
Bonzani RA; Stricker HJ; Peabody JO; Menon M
J Urol; 1998 Dec; 160(6 Pt 2):2446-9. PubMed ID: 9817400
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
7. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.
Hillner BE; Roberts JD
J Natl Cancer Inst; 2000 Nov; 92(21):1704-6. PubMed ID: 11058606
[No Abstract] [Full Text] [Related]
8. Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica.
Morrison BF; Aiken WD; Reid ME
Rev Panam Salud Publica; 2011 Jun; 29(6):404-8. PubMed ID: 21829963
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
Weight CJ; Klein EA; Jones JS
Cancer; 2008 May; 112(10):2195-201. PubMed ID: 18393326
[TBL] [Abstract][Full Text] [Related]
10. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
Nygård R; Norum J; Due J
Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
[TBL] [Abstract][Full Text] [Related]
11. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
12. Subcapsular orchiectomy versus total orchiectomy and LHRH analogue in the treatment of hormone-sensitive metastatic prostate cancer: a different perspective in evaluation of the psychosocial effects.
Selvi I; Basar H
Support Care Cancer; 2020 Sep; 28(9):4313-4326. PubMed ID: 31912363
[TBL] [Abstract][Full Text] [Related]
13. Medicare reimbursement and prescribing hormone therapy for prostate cancer.
Keating NL
J Natl Cancer Inst; 2010 Dec; 102(24):1814-5. PubMed ID: 21131579
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
15. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.
Chang SL; Liao JC; Shinghal R
J Urol; 2009 Jul; 182(1):255-60; discussion 261. PubMed ID: 19450844
[TBL] [Abstract][Full Text] [Related]
16. Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer.
Garje R; Chennamadhavuni A; Mott SL; Chambers IM; Gellhaus P; Zakharia Y; Brown JA
Clin Genitourin Cancer; 2020 Apr; 18(2):e157-e166. PubMed ID: 31956009
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.
Potosky AL; Knopf K; Clegg LX; Albertsen PC; Stanford JL; Hamilton AS; Gilliland FD; Eley JW; Stephenson RA; Hoffman RM
J Clin Oncol; 2001 Sep; 19(17):3750-7. PubMed ID: 11533098
[TBL] [Abstract][Full Text] [Related]
18. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
20. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
